lenvatinib
Lenvima (lenvatinib) is an oral multi-kinase inhibitor from Eisai that blocks VEGF and FGF receptors driving tumour blood supply. It is used in radioactive iodine-refractory thyroid cancer, advanced kidney cancer and, with pembrolizumab, in endometrial cancer.
This page is based on FDA prescribing information and the EMA medicine record for lenvatinib, cross-checked with DailyMed and MedlinePlus; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
A tumour builds two lifelines: new blood vessels for supplies, and growth signals through receptor antennas. Lenvatinib cuts both at once - it blocks the VEGF and FGF docking stations so no new supply lines are built and fewer growth orders get through, and the tumour's expansion stalls.
In simple terms
Cancers depend on new blood vessels and on growth signals received through receptor proteins. Lenvatinib blocks several of these receptors, including those for VEGF and FGF. This reduces tumour blood vessel formation and interrupts growth signalling. The result is slower growth and, in many patients, shrinkage of thyroid and kidney cancers.
In depth
Lenvatinib is an oral small-molecule inhibitor of VEGFR1-3, FGFR1-4, PDGFR-alpha, RET and KIT tyrosine kinases. Dual VEGFR/FGFR blockade suppresses angiogenesis and overcomes FGFR-mediated resistance to pure VEGF-pathway inhibition. In radioactive iodine-refractory differentiated thyroid cancer it markedly prolonged progression-free survival, and combinations with pembrolizumab or everolimus extend its use in renal cell carcinoma.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
A tumour builds two lifelines
- Cancers depend on new blood vessels and on growth signals received through receptor proteins.
- Lenvatinib blocks several of these receptors, including those for VEGF and FGF.
- This reduces tumour blood vessel formation and interrupts growth signalling.
- The result is slower growth and, in many patients, shrinkage of thyroid and kidney cancers.
Target: VEGFR1-3, FGFR1-4, PDGFR-alpha, RET and KIT kinases
Receptor kinases that drive tumour blood vessel formation and growth signals; blocking several at once starves the tumour and slows its proliferation.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- Treatment of adults with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer
- With pembrolizumab, for the first-line treatment of adults with advanced renal cell carcinoma
- With everolimus, for the treatment of adults with advanced renal cell carcinoma following one prior anti-angiogenic therapy
Approved uses in European Union
EMA- As monotherapy, for progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hurthle cell) thyroid carcinoma refractory to radioactive iodine in adults
Official sources
The statements on this page trace back to these records.
- Lenvima (lenvatinib) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- DailyMed: Lenvima (lenvatinib) label
DailyMed, U.S. National Library of Medicine
- U.S. Food and Drug Administration: lenvatinib prescribing information
U.S. Food and Drug Administration
- MedlinePlus: lenvatinib
MedlinePlus, U.S. National Library of Medicine
- National Cancer Institute: lenvatinib mesylate
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.